Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 20/20 | 1.00 |
| ▸ | DAO | P14920 | 2/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 2/20 | 1.00 |
| ▸ | LOX | P28300 | 2/20 | 0.80 |
| ▸ | LOXL3 | P58215 | 2/20 | 0.80 |
| ▸ | LOXL1 | Q08397 | 2/20 | 0.80 |
| ▸ | LOXL4 | Q96JB6 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20699521 | 1.00 | LOXL2 (1.00) | LOXL2DAOAOC3LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL20699622 | 0.99 | LOXL2 (1.00) | LOXL2DAOAOC3LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL20699623 | 0.99 | LOXL2 (1.00) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL19255387 | 0.94 | LOXL2 (0.93) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL20699590 | 0.94 | LOXL2 (0.93) | LOXL2DAOAOC3LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL22497142 | 0.93 | LOXL2 (0.93) | LOXL2DAOAOC3LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL22497141 | 0.93 | LOXL2 (0.93) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL20699516 | 0.92 | LOXL2 (1.00) | LOXL2DAOAOC3LOXLOXL3 | |
| SCHEMBL19254720 | 0.92 | LOXL2 (1.00) | LOXL2DAOAOC3LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL20699658 | 0.91 | LOXL2 (1.00) | LOXL2DAOAOC3LOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-10-08 | — | — | US | claimed |
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | claimed |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-02-07 | — | — | US | claimed |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-10-08 | — | — | US | disclosed |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-10-08 | — | — | US | disclosed |
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-02-07 | — | — | US | disclosed |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-02-07 | — | — | US | disclosed |
| WO-2017136870-A9 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2018-02-15 | — | — | WO | disclosed |
| WO-2017136870-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | IDO1, IDO2, INMT | LOXL2 24/4885DAO 4/4885AOC3 27/4885 |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | LOXL2 24/4885DAO 4/4885AOC3 27/4885 |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | LOXL2 24/4885DAO 4/4885AOC3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.